Merck & Co., Inc.
MRK XNYS
$111.38
-0.95 (-0.85%)
▼
15-min delayed
Open
$112.38
High
$113.01
Low
$111.18
Volume
5.73M
Market Cap
$275.09B
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $16.29B | $-4,243,000,000 | $-1.72 |
| FY 2025 | $65.01B | $18.26B | $7.30 |
| Q3 2025 | $17.28B | $5.79B | $2.32 |
| Q2 2025 | $15.81B | $4.43B | $1.76 |
Earnings & Analyst Ratings
Next Earnings:
Tue, Aug 4, 2026
Calendar →
TickerDaily Coverage
Stock Market Today, April 19, 2026: Earnings Week Ahead Shapes Trading Strategy
Market News
David Brooks · Apr 20, 2026
With mega-cap earnings dominating next week's calendar, the stock market today sets up for a...
Healthcare Stocks This Week: XLV Ends Mixed as Pharma Giants Face Margin Pressures (Mar 23–27, 2026)
Market News
David Brooks · Mar 27, 2026
The healthcare sector finished Friday, March 27, 2026 in neutral territory as investor focus...
View All Coverage →
Get MRK Alerts
Stay ahead with breaking news, price alerts, and expert analysis on Merck & Co., Inc..
Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.